Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

Blood

Volumn 119, Issue 18, 2012, Pages 4253-4263

  Nieborowska Skorska, Margaret ^a   Kopinski, Piotr K ^a   Ray, Regina ^a   Hoser, Grazyna ^b   Ngaba, Danielle ^a   Flis, Sylwia ^a   Cramer, Kimberly ^a   Reddy, Mamatha M ^c   Koptyra, Mateusz ^a   Penserga, Tyrone ^a   Glodkowska Mrowka, Eliza ^d   Bolton, Elisabeth ^a   Holyoake, Tessa L ^e   Eaves, Connie J ^f   Cerny Reiterer, Sabine ^g   Valent, Peter ^g   Hochhaus, Andreas ^h   Hughes, Timothy P ⁱ   Van Der Kuip, Heiko ^j   Sattler, Martin ^c   Wiktor Jedrzejczak, Wieslaw ^d   Richardson, Christine ^k   Dorrance, Adrienne ^l   Stoklosa, Tomasz ^d   Williams, David A ^l   Skorski, Tomasz ^a   more..

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h JENA UNIVERSITY HOSPITAL   (Germany)

ⁱ UNIVERSITY OF ADELAIDE   (Australia)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k University of North Carolina at Charlotte   (United States)

^l HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CATALASE; COMPLEMENTARY DNA; GUANOSINE TRIPHOSPHATASE; MESSENGER RNA; PEPTIDE APTAMER; RAC2 PROTEIN; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA;

ARTICLE; CANCER RELAPSE; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DNA DAMAGE; GENE DELETION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 84860819704     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-385658     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
2. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441-453. (Pubitemid 46823444)
3. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396-409.
4. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254-2264.
5. Slupphaug G, Kavli B, Krokan HE. The interacting pathways for prevention and repair of oxidative DNA damage. Mutat Res. 2003;531(1-2):231-251. (Pubitemid 37456735)
6. Sallmyr A, Fan J, Datta K, et al. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood. 2008;111(6):3173-3182.
7. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006;108(1):319-327. (Pubitemid 43990645)
8. Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 2004;104(12):3746-3753. (Pubitemid 39564453)
9. Walz C, Crowley BJ, Hudon HE, et al. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem. 2006;281(26):18177-18183. (Pubitemid 44035617)
10. Acín-Pérez R, Bayona-Bafaluy MP, Fernandez-Silva P, et al. Respiratory complex III is required to maintain complex I in mammalian mitochondria. Mol Cell. 2004;13(6):805-815. (Pubitemid 38438476)
11. Wang W, Fang H, Groom L, et al. Superoxide flashes in single mitochondria. Cell. 2008;134(2):279-290. (Pubitemid 352010332)
12. Skorski T, Wlodarski P, Daheron L, et al. BCR/ ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc Natl Acad Sci U S A. 1998;95(20):11858-11862. (Pubitemid 28460504)
13. Hitosugi T, Kang S, Vander Heiden MG, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009;2(97):ra73.
14. Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia. 2008;22(10):1969-1972.
15. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science. 1989;246(4929):500-503. (Pubitemid 19273941)
16. Han F, Da T, Riobo NA, Becker LB. Early mitochondrial dysfunction in electron transfer activity and reactive oxygen species generation after cardiac arrest. Crit Care Med. 2008;36(11 suppl):S447-S453.
17. Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009;119(3):573-581.
18. Wolff NC, Ilaria RL Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood. 2001;98(9):2808-2816.
19. Slupianek A, Poplawski T, Jozwiakowski SK, et al. BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Res. 2011;71(3):842-851.
20. Capizzi RL, Jameson JW. A table for the estimation of the spontaneous mutation rate of cells in culture. Mutat Res. 1973;17(1):147-148.
21. Sloma I, Jiang X, Eaves AC, Eaves CJ. Insights into the stem cells of chronic myeloid leukemia. Leukemia. 2010;24(11):1823-1833.
22. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160(1):1-40. (Pubitemid 43227479)
23. Smiley ST, Reers M, Mottola-Hartshorn C, et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A. 1991;88(9):3671-3675. (Pubitemid 21916685)
24. Smith RA, Kelso GF, Blaikie FH, et al. Using mitochondria- targeted molecules to study mitochondrial radical production and its consequences. Biochem Soc Trans. 2003;31(Pt 6):1295-1299. (Pubitemid 38030959)
25. Gonzalez C, Agapito MT, Rocher A, et al. Chemoreception in the context of the general biology of ROS. Respir Physiol Neurobiol. 2007;157(1):30-44. (Pubitemid 46629052)
26. Werner E, Werb Z. Integrins engage mitochondrial function for signal transduction by a mechanism dependent on Rho GTPases. J Cell Biol. 2002;158(2):357-368.
27. Shutes A, Onesto C, Picard V, Leblond B, Schweighoffer F, Der CJ. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem. 2007;282(49):35666-35678. (Pubitemid 350277149)
28. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A. 2004;101(20):7618-7623. (Pubitemid 38658078)
29. Pai SY, Kim C, Williams DA. Rac GTPases in human diseases. Dis Markers. 2010;29(3-4):177-187.
30. Schriner SE, Linford NJ, Martin GM, et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science. 2005;308(5730):1909-1911. (Pubitemid 40941874)
31. Sorel N, Bonnet ML, Guillier M, Guilhot F, Brizard A, Turhan AG. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun. 2004;323(3):728-730. (Pubitemid 39243379)
32. Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer. 2002;2(5):351-360. (Pubitemid 37328948)
33. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463(7281):676-680.
34. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20):5565-5572.
35. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem. 1998;273(11):6297-6302. (Pubitemid 28144719)
36. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657-667. (Pubitemid 39063268)
37. Samudio I, Kurinna S, Ruvolo P, et al. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol Cancer Ther. 2008;7(5):1130-1139.
38. Simsek T, Kocabas F, Zheng J, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell. 2010;7(3):380-390.
39. Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol. 2006;91(5):807-819. (Pubitemid 44266577)
40. Barnes K, McIntosh E, Whetton AD, Daley GQ, Bentley J, Baldwin SA. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene. 2005;24(20):3257-3267. (Pubitemid 40695107)
41. Amarante-Mendes GP, Naekyung Kim C, Liu L, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998;91(5):1700-1705. (Pubitemid 28110335)
42. Kluza J, Jendoubi M, Ballot C, et al. Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells. PLoS One. 2011;6(7):e21924.
43. Kim JH, Chu SC, Gramlich JL, et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005;105(4):1717-1723. (Pubitemid 40223695)
44. Welch HC, Coadwell WJ, Stephens LR, Hawkins PT. Phosphoinositide 3-kinase-dependent activation of Rac. FEBS Lett. 2003;546(1):93-97. (Pubitemid 36782287)
45. Harnois T, Constantin B, Rioux A, Grenioux E, Kitzis A, Bourmeyster N. Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl. Oncogene. 2003;22(41):6445-6454. (Pubitemid 37281691)
46. Thomas EK, Cancelas JA, Chae HD, et al. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell. 2007;12(5):467-478. (Pubitemid 350046406)
47. Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood. 2010;116(1):81-84.
48. Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res. 2008;68(23):9624-9633.
49. Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst. 2007;99(9):680-693. (Pubitemid 47073530)
50. Haferlach C, Bacher U, Schnittger S, Weiss T, Kern W, Haferlach T. Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment. Leukemia. 2010;24(3):638-640.